Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
2(20%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_1
1
10%
Ph phase_2
6
60%
Ph phase_3
2
20%

Phase Distribution

1

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
6(66.7%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(6)
Other(2)

Detailed Status

Completed6
unknown2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 26 (66.7%)
Phase 32 (22.2%)

Trials by Status

unknown220%
completed660%
active_not_recruiting220%

Recent Activity

2 active trials
Showing 5 of 10
completedphase_2

AMX0035 and Progressive Supranuclear Palsy

NCT06122662
active_not_recruitingphase_2

AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034
completedphase_2

Open Label Extension Study of AMX0035 in Patients With ALS

NCT03488524
completedphase_2

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

NCT03533257
completedphase_3

Extension Study Evaluating The Safety And Tolerability of AMX0035

NCT05619783
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06122662Phase 2

AMX0035 and Progressive Supranuclear Palsy

Completed
NCT05676034Phase 2

AMX0035 in Adult Patients With Wolfram Syndrome

Active Not Recruiting
NCT03488524Phase 2

Open Label Extension Study of AMX0035 in Patients With ALS

Completed
NCT03533257Phase 2

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

Completed
NCT05619783Phase 3

Extension Study Evaluating The Safety And Tolerability of AMX0035

Completed
NCT05021536Phase 3

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

Active Not Recruiting
NCT03127514Phase 2

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT04987671Phase 1

Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

Unknown
NCT04516096Phase 2

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT05286372

An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10